Indian Pharma industry moving towards formulations

Indian Pharma industry is slowing moving up the value chain. Earlier it used to manufacture active pharmaceutical ingredient at low cost compared to world. Now with competition from China, which provides API at 15-20% low cost, it makes sense to shift focus elsewhere. Many top companies like Lupin, Novartis, Ranbaxy have less revenue stream from API than from formulations. There could also be the reason that formulation business has grown faster than APIs for some companies. API is low scale commodity with low margin. Moreover, with a large number of patent expiries in developed markets like the US and Europe, Indian companies, with skills to develop and manufacture low-cost generic drugs, see a much more lucrative opportunity there than utilising their capacities for manufacturing APIs.
Read More

  • No Image
    Venus Biosciences Pvt Ltd

    Venus Biosciences Pvt Ltd was started earlier as partnership firm in 2005 and later converted to private limited company in 2008 . The company has two directors namely, Mr. Rag

  • No Image
    Venus Remedies Ltd

    Venus Remedies Limited is a fully integrated Company, known around the globe for its research and development initiatives and breakthroughs. It is supported by world class manuf

  • No Image
    Vikram Thermo India Ltd

    Vikram Thermo India Ltd., was born in 1984 at Chhatral, near Ahmedabad first time in India with its first plant for manufacturing Diphenyl Oxide with the name of Vikram Enterpri

  • No Image
    Virchow Laboratories Pvt Ltd

    Virchow Group comprises of six active pharmaceutical ingredient (API) and drug intermediate manufacturing units and two biotech units. Incorporated in 1981, the flagship company